Back to Authors

Wenderfer, Scott E

0000-0002-8991-8277

Mayo Clinic

Division of Pediatric Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.

Citations 2

Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis
Barbour, Sean J. , Coppo, Rosanna , Er, Lee, Pillebout, Évangéline , Russo, María Luisa , Alpers, Charles E. , Ferrario, Franco, Jennette, J. Charles , Roberts, Ian S.D. , Cook, H. Terence , Ding, Jie , Su, Baige , Zhong, Xuhui, Zand, Ladan , Lucchetti, Laura , Katafuchi, Ritsuko , Shima, Yuko , Yoshikawa, Norishige, Ichikawa, Daisuke , Suzuki, Yusuke , Park, Catherine , Nelson, Raoul D., Narus, JoAnn Hansen , Wenderfer, Scott E. , Monteiro, Renato C. , Nakatani, Shinya , Mastrangelo, Antonio , Nuutinen, Matti, Koskela, Mikael , Weber, Lutz T. , Hackl, Ágnes, Pecoraro, Carmine, Yokoo, Takashi , Ito, Takafumi, Conti, Giovanni , Materassi, Marco , Zhang, Hong , Shi, Sufang , Liu, Zhihong , Ávila-Casado, Carmen , Bajema, Ingeborg M., Barreca, Antonella , Comstock, Jessica, Cornea, Virgilius , Eldin, Karen W. , Hernandez, Loren Herrera, Hou, Jean , Lin, Mercury, Messias, Nidia , Tokola, Heikki , DʼArmiento, Maria , Sannier, Aurélie , Jennette, J Charles , Ding, Jie , Zand, Ladan , Peruzzi, Licia , Shima, Yuko , Ichikawa, Daisuke , Suzuki, Yusuke , Narus, JoAnn H , Wenderfer, Scott E , Geetha, Duvuru , Daugas, Eric , Monteiro, Renato C , Tsuboi, Nobuo , Yokoo, Takashi , Fujimoto, Shouichi , Materassi, Marco , Shi, Sufang , Liu, Zhi-Hong , Tesar, Vladimir , Maixnerova, Dita , Barreca, Antonella , Eldin, Karen , Joh, Kensuke , Muda, Andrea Onetti , Pagni, Fabio , Diomedi-Camassei, Francesca , Tokola, Heikki , Seidl, Maximilian , Sannier, Aurélie , Soares, Maria Fernanda , Wang, Suxia , Zeng, Caihong , Coppo, Rosanna , Fogo, Agnes B. , Fervenza, Fernando C. , Murer, Luisa , Wyatt, Robert J. , Pohl, Martin, Santoro, Domenico , Tesař, Vladimı́r , Becker, Jan Ulrich , Diomedi‐Camassei, Francesca , Rosenberg, Avi Z. , Haas, Mark

Clinical Journal of the American Society of Nephrology | January 23, 2024 | Volume: 19 | Issue: 4 | Pages: 438-451

10.2215/cjn.0000000000000398 Get It

Background Nephritis is a common manifestation of IgA vasculitis and is morphologically indistinguishable from IgA nephropathy. While MEST-C scores are predictive of kidney outcomes in IgA nephropathy, their value in IgA vasculitis nephritis has not been investigated in large multiethnic cohorts. Methods Biopsies from 262 children and 99 adults with IgA vasculitis nephritis ( N =361) from 23 centers in North America, Europe, and Asia were independently scored by three pathologists. MEST-C scores were assessed for correlation with eGFR/proteinuria at biopsy. Because most patients ( N =309, 86%) received immunosuppression, risk factors for outcomes were evaluated in this group using latent class mixed models to identify classes of eGFR trajectories over a median follow-up of 2.7 years (interquartile range, 1.2–5.1). Clinical and histologic parameters associated with each class were determined using logistic regression. Results M, E, T, and C scores were correlated with either eGFR or proteinuria at biopsy. Two classes were identified by latent class mixed model, one with initial improvement in eGFR followed by a late decline (class 1, N =91) and another with stable eGFR (class 2, N =218). Class 1 was associated with a higher risk of an established kidney outcome (time to ≥30% decline in eGFR or kidney failure; hazard ratio, 5.84; 95% confidence interval, 2.37 to 14.4). Among MEST-C scores, only E1 was associated with class 1 by multivariable analysis. Other factors associated with class 1 were age 18 years and younger, male sex, lower eGFR at biopsy, and extrarenal noncutaneous disease. Fibrous crescents without active changes were associated with class 2. Conclusions Kidney outcome in patients with biopsied IgA vasculitis nephritis treated with immunosuppression was determined by clinical risk factors and endocapillary hypercellularity (E1) and fibrous crescents, which are features that are not part of the International Study of Diseases of Children classification.
Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study
Maliakkal, Joseph , Hicks, John , Michael, Mini , Selewski, David T. , Twombley, Katherine , Rheault, Michelle N. , Seamon, Meredith, Misurac, Jason , Tran, Cheryl L. , Reyes, Loretta , Onder, Ali Mirza , Constantinescu, Alexandru R. , Singh, Vaishali , Pan, Cynthia G., Omoloja, Abiodun , Wu, Qiang , Smoyer, William E., Hidalgo, Guillermo , Wenderfer, Scott E. , Misurac, Jason M , Wenderfer, Scott E , Twombley, Katherine E , Flynn, Joseph T. , Smoyer, William E.

Journal of Clinical Medicine | July 27, 2020 | Volume: 9 | Issue: 8 | Pages: 2385

10.3390/jcm9082385 Get It

There is no evidence-based definition for diagnosing crescentic glomerulonephritis. The prognostic implications of crescentic lesions on kidney biopsy have not been quantified. Our objective was to determine risk factors for end-stage kidney disease (ESKD) in patients with glomerulonephritis and crescents on kidney biopsy. A query of the Pediatric Nephrology Research Consortium’s Pediatric Glomerulonephritis with Crescents registry identified 305 patients from 15 centers. A retrospective cohort study was performed with ESKD as the primary outcome. Median age at biopsy was 11 years (range 1–21). The percentage of crescents was 3–100% (median 20%). Etiologies included IgA nephropathy (23%), lupus (21%), IgA vasculitis (19%) and ANCA-associated GN (13%), post-infectious GN (5%), and anti-glomerular basement membrane disease (3%). The prevalence of ESKD was 12% at one year and 16% at last follow-up (median = 3 years, range 1–11). Median time to ESKD was 100 days. Risk factors for ESKD included %crescents, presence of fibrous crescents, estimated GFR, and hypertension at biopsy. For each 1% increase in %crescents, there was a 3% decrease in log odds of 1-year renal survival (p = 0.003) and a 2% decrease in log odds of renal survival at last follow-up (p < 0.001). These findings provide an evidence base for enrollment criteria for crescentic glomerulonephritis in future clinical trials.